Phibro Animal Health (PAHC) Competitors

$34.37 -1.78 (-4.92%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$34.33 -0.04 (-0.12%)

As of 05/15/2026 06:41 PM Eastern

PAHC vs. CNTA, COGT, SRRK, IMVT, and XENE

Should you buy Phibro Animal Health stock or one of its competitors? MarketBeat compares Phibro Animal Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Phibro Animal Health include Centessa Pharmaceuticals (CNTA), Cogent Biosciences (COGT), Scholar Rock (SRRK), Immunovant (IMVT), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry.

How does Phibro Animal Health compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Phibro Animal Health has a net margin of 6.35% compared to Centessa Pharmaceuticals' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Phibro Animal Health	6.35%	37.14%	8.57%

In the previous week, Phibro Animal Health had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 7 mentions for Phibro Animal Health and 5 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.41 beat Phibro Animal Health's score of 0.30 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phibro Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phibro Animal Health has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	393.87	-$197.53M	-$1.79	N/A
Phibro Animal Health	$1.50B	0.93	$48.26M	$2.33	14.75

Centessa Pharmaceuticals currently has a consensus price target of $40.70, indicating a potential upside of 2.80%. Phibro Animal Health has a consensus price target of $38.80, indicating a potential upside of 12.89%. Given Phibro Animal Health's stronger consensus rating and higher possible upside, analysts plainly believe Phibro Animal Health is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Centessa Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Phibro Animal Health beats Centessa Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Phibro Animal Health compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

In the previous week, Phibro Animal Health had 4 more articles in the media than Cogent Biosciences. MarketBeat recorded 7 mentions for Phibro Animal Health and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.29 beat Phibro Animal Health's score of 0.30 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phibro Animal Health has a net margin of 6.35% compared to Cogent Biosciences' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Phibro Animal Health	6.35%	37.14%	8.57%

99.3% of Phibro Animal Health shares are held by institutional investors. 7.3% of Cogent Biosciences shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Phibro Animal Health has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Phibro Animal Health	$1.50B	0.93	$48.26M	$2.33	14.75

Cogent Biosciences has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Cogent Biosciences currently has a consensus price target of $43.73, indicating a potential upside of 33.80%. Phibro Animal Health has a consensus price target of $38.80, indicating a potential upside of 12.89%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cogent Biosciences is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Summary

Phibro Animal Health beats Cogent Biosciences on 11 of the 16 factors compared between the two stocks.

How does Phibro Animal Health compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Scholar Rock had 11 more articles in the media than Phibro Animal Health. MarketBeat recorded 18 mentions for Scholar Rock and 7 mentions for Phibro Animal Health. Scholar Rock's average media sentiment score of 0.79 beat Phibro Animal Health's score of 0.30 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phibro Animal Health has a net margin of 6.35% compared to Scholar Rock's net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Phibro Animal Health	6.35%	37.14%	8.57%

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Phibro Animal Health has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Phibro Animal Health	$1.50B	0.93	$48.26M	$2.33	14.75

Scholar Rock has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Scholar Rock currently has a consensus price target of $56.00, indicating a potential upside of 13.48%. Phibro Animal Health has a consensus price target of $38.80, indicating a potential upside of 12.89%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts plainly believe Scholar Rock is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.17
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Summary

Phibro Animal Health beats Scholar Rock on 9 of the 16 factors compared between the two stocks.

How does Phibro Animal Health compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Phibro Animal Health had 4 more articles in the media than Immunovant. MarketBeat recorded 7 mentions for Phibro Animal Health and 3 mentions for Immunovant. Immunovant's average media sentiment score of 0.89 beat Phibro Animal Health's score of 0.30 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phibro Animal Health has a net margin of 6.35% compared to Immunovant's net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-63.17%	-58.01%
Phibro Animal Health	6.35%	37.14%	8.57%

Phibro Animal Health has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$413.84M	-$2.69	N/A
Phibro Animal Health	$1.50B	0.93	$48.26M	$2.33	14.75

47.1% of Immunovant shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Immunovant currently has a consensus price target of $32.44, indicating a potential upside of 18.02%. Phibro Animal Health has a consensus price target of $38.80, indicating a potential upside of 12.89%. Given Immunovant's stronger consensus rating and higher probable upside, analysts plainly believe Immunovant is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Immunovant has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Summary

Phibro Animal Health beats Immunovant on 11 of the 16 factors compared between the two stocks.

How does Phibro Animal Health compare to Xenon Pharmaceuticals?

Phibro Animal Health (NASDAQ:PAHC) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, Xenon Pharmaceuticals had 11 more articles in the media than Phibro Animal Health. MarketBeat recorded 18 mentions for Xenon Pharmaceuticals and 7 mentions for Phibro Animal Health. Xenon Pharmaceuticals' average media sentiment score of 1.04 beat Phibro Animal Health's score of 0.30 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phibro Animal Health has a net margin of 6.35% compared to Xenon Pharmaceuticals' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

Phibro Animal Health has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.50B	0.93	$48.26M	$2.33	14.75
Xenon Pharmaceuticals	N/A	N/A	-$345.91M	-$4.70	N/A

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Phibro Animal Health presently has a consensus price target of $38.80, indicating a potential upside of 12.89%. Xenon Pharmaceuticals has a consensus price target of $77.07, indicating a potential upside of 41.69%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Phibro Animal Health has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

Summary

Phibro Animal Health beats Xenon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Phibro Animal Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PAHC vs. The Competition

Export

Metric	Phibro Animal Health	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.39B	$8.17B	$6.38B	$12.30B
Dividend Yield	1.33%	2.54%	2.81%	5.26%
P/E Ratio	14.75	15.79	20.66	25.27
Price / Sales	0.93	7.35	553.14	73.66
Price / Cash	10.51	16.48	42.43	54.86
Price / Book	3.85	3.78	9.87	6.90
Net Income	$48.26M	$223.05M	$3.57B	$334.66M
7 Day Performance	-14.08%	-3.49%	0.23%	0.12%
1 Month Performance	-39.78%	-2.59%	-2.54%	-0.18%
1 Year Performance	43.21%	-0.20%	33.54%	30.62%

Phibro Animal Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PAHC Phibro Animal Health	4.4302 of 5 stars	$34.37 -4.9%	$38.80 +12.9%	+43.2%	$1.39B	$1.50B	14.75	2,475	Analyst Forecast Gap Down
CNTA Centessa Pharmaceuticals	2.0932 of 5 stars	$39.61 +0.1%	$40.70 +2.8%	+216.5%	$5.91B	N/A	N/A	200
COGT Cogent Biosciences	3.1776 of 5 stars	$34.53 +1.3%	$43.73 +26.6%	+569.7%	$5.90B	N/A	N/A	80
SRRK Scholar Rock	2.4294 of 5 stars	$49.19 +1.7%	$56.00 +13.8%	+61.5%	$5.89B	N/A	N/A	140	Analyst Revision
IMVT Immunovant	2.1205 of 5 stars	$28.65 -1.4%	$32.44 +13.2%	+90.1%	$5.83B	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PAHC) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phibro Animal Health (PAHC) Competitors

PAHC vs. CNTA, COGT, SRRK, IMVT, and XENE

How does Phibro Animal Health compare to Centessa Pharmaceuticals?

Summary

How does Phibro Animal Health compare to Cogent Biosciences?

Summary

How does Phibro Animal Health compare to Scholar Rock?

Summary

How does Phibro Animal Health compare to Immunovant?

Summary

How does Phibro Animal Health compare to Xenon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC vs. The Competition

Phibro Animal Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phibro Animal Health (PAHC) Competitors

PAHC vs. CNTA, COGT, SRRK, IMVT, and XENE

How does Phibro Animal Health compare to Centessa Pharmaceuticals?

Is CNTA or PAHC more profitable?

Does the media favor CNTA or PAHC?

Which has preferable valuation & earnings, CNTA or PAHC?

Do analysts prefer CNTA or PAHC?

Which has more volatility & risk, CNTA or PAHC?

Do insiders and institutionals hold more shares of CNTA or PAHC?

Summary

How does Phibro Animal Health compare to Cogent Biosciences?

Does the media favor COGT or PAHC?

Is COGT or PAHC more profitable?

Do insiders and institutionals hold more shares of COGT or PAHC?

Which has preferable valuation & earnings, COGT or PAHC?

Which has more volatility & risk, COGT or PAHC?

Do analysts prefer COGT or PAHC?

Summary

How does Phibro Animal Health compare to Scholar Rock?

Does the media favor SRRK or PAHC?

Is SRRK or PAHC more profitable?

Do institutionals and insiders hold more shares of SRRK or PAHC?

Which has better earnings & valuation, SRRK or PAHC?

Which has more volatility and risk, SRRK or PAHC?

Do analysts prefer SRRK or PAHC?

Summary

How does Phibro Animal Health compare to Immunovant?

Does the media favor IMVT or PAHC?

Is IMVT or PAHC more profitable?

Which has better earnings & valuation, IMVT or PAHC?

Do institutionals and insiders hold more shares of IMVT or PAHC?

Do analysts prefer IMVT or PAHC?

Which has more volatility and risk, IMVT or PAHC?

Summary

How does Phibro Animal Health compare to Xenon Pharmaceuticals?

Does the media refer more to PAHC or XENE?

Is PAHC or XENE more profitable?

Which has better earnings & valuation, PAHC or XENE?

Do insiders & institutionals believe in PAHC or XENE?

Do analysts recommend PAHC or XENE?

Which has more risk & volatility, PAHC or XENE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC vs. The Competition

Phibro Animal Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools